Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/363611


2006 Industry Dynamics: Lessons to Be Learned


Description: Stunning successes and startling failures highlight 2006’s pharmaceutical industry. In this year-end retrospective report, we contemplate the importance of these developments and what they mean to the pharmaceutical industry. Additionaly, we asked industry experts for their opinions and integrated their commentary and analysis into this report.

Get the Answers You Need to Shape Your Strategy
The winning technology of 2006 continues to be a major success for the drug industry; however, even successful and well-tried innovations can meet with disaster. Which technology has Decision Resources deemed most lucrative in 2006, and why is its potential for commercial success so great? Which particular agent proves that even the most promising technologies are not immune to the risks inherent in development?
2006 saw more development and deals within a group of products that is poised to dramatically change the way diseases are currently treated. What is this group of products, and what were the major business strategies and deals within this group in 2006?
Competition between innovator companies and generics companies has never been higher as these groups battle to control drug markets; innovator companies continue to face unrelenting pressure from generics companies that want to invalidate drug patents and gain early market entry for their drugs. What were 2006’s developments on the generics front line? What strategies are innovator companies employing to ward off generics competition?
A prominent strategy of the pharmaceutical industry—historically employed to bolster thin product pipelines and increase presence in more markets—continues in 2006. However, this strategy is threatening the productivity and innovation of the largest pharmaceutical manufacturers. What longstanding practice in the pharmaceutical industry is counterproductive in today’s industry? How may the recent decisions of one major company serve as a lesson?


Contents: Executive Summary 3
Strategic Considerations 3
Stakeholder Implications 3
2006 in Review 4
2006’s Winning Technology 4
Worldwide Sales and Blockbusters 4
2006 MAb Approvals 8
Big Pharma’s Frenzied Acquisition of MAb Companies 8
Disaster Strikes Tysabri 9
Sarah W Fuller, Andrea S Witt, Ph D , Decision Resources
The Silver Lining 11
Generics’ Bloody Battlefield 11
Authorized Generics 12
At-Risk Launch of Generics 15
Paul King, M S , J D , Member of the District of Columbia Bar, KING PLLC, Capitol Hill
World’s Largest Generics Company 16
Paul King, M S , J D , Member of the District of Columbia Bar, KING PLLC, Capitol Hill
Consolidation Woes 17
Serial Consolidation in Big Pharma 17
Barrie G James, Ph D , Pharma Strategy Consulting
European Midsize Pharma—End of the Beginning or Beginning of the End? 19
Barrie G James, Ph D , Pharma Strategy Consulting
Generics Companies—Bulking Up in 2006 20
Pfizer Burns 22
Four Major Announcements in Five Days 24
Radical Changes at Pfizer—R&D Emphasis Still Out of Touch with Reality 25
John Ansell, M A , John Ansell Consultancy
Two Years of Frustrating Productivity 25
Problems of Size 26
Nose-Diving Productivity 26
Rise and Fall of Combination Products 26
2006’s Major Battle for Dominance in Stent Markets 27
2006 Crisis—Thrombosis Linked to Drug-Eluting Stents 30
Outlook 31
Appendix 32

Figures
1. MAbs: From Mouse to Human 5
2. $13 Billion Monoclonal Antibody Sales, First 3 Quarters of 2006 6
3. Tysabri 2004-2006 Timeline 9
4. Dollar Value of Branded Drugs Going Off-Patent, 1995-2010 12
5. Receipts of Original Abbreviated New Drug Applications (ANDAs), 2001-2006 13
6. Top 1984 Pharmaceutical Companies Compared with Top 2004 Generics Companies 16
7. Serial Consolidation in the Pharmaceutical Industry 18
8. Market Capitalization of Select Companies, December 8, 2006 24
9. Drug-Eluting Stents 28
10. Worldwide Sales Comparisons: Boston Scientific’s Taxus Stent vs. Cordis/
Johnson & Johnson’s Cypher Stent 29

Tables
1. Prices of Select Cancer Therapies in the United States, 2001-2005 7
2. Branded Drugs Authorized as Generics in 2006 13
3. Generics Companies Bulk Up, 2006 21
4. Select Pfizer Deals, January to November 2006 23


Companies Mentioned Abbott Laboratories Abgenix Abmaxis Abrika Pharmaceuticals Actavis Akzo Nobel Allen Allergan Alnylam Pharmaceuticals Altana Amgen Apotex Astex Therapeutics AstraZeneca Banyu Pharmaceuticals Barr Pharmaceuticals Baxter Bayer Be-Tabs Pharmaceuticals Betapharm Biogen Idec Biomarin Pharmaceutical Boston Scientific Bristol-Myers Squibb Cambridge Antibody Technology Conor Medsystems Dr. Reddy’s Laboratories Elan Ethimed Genentech Greenstone Guidant Hospira ImClone Ivax John Ansell Consultancy Johnson & Johnson King PLLC Lehman Brothers Mayne Pharmaceuticals Merck Merck KGaA Merck-Serono Biopharmaceuticals Millennium Research Group Monogram Biosciences Mundogen Neurocrine Biosciences NicOx Novartis Ophthalmics Noxxon Pharma Nycomed Odyssey Thera OrthovitaOscient Pharmaceuticals OSG Norwich Par Pfizer Pfizer Consumer Healthcare Pharma Strategy Consulting Pliva PowderMed Procter & Gamble Quark Biotech Ranbaxy Laboratories Rinat Neuroscience Roche Sandoz Sanofi -Aventis Savient Schering-Plough Schwarz Pharma Sekhsaria Chemicals Shionogi Spectrum Tanabe TeGenero Tepnel Terapia Teva Pharmaceuticals Tianjin Hualida Biotechnology TransTech Pharma Uso Racional Watson Pharmaceuticals


Ordering: Order Online - visit http://www.researchandmarkets.com/reports/363611

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 21/11/2009 23:27:09
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
2006 Industry Dynamics: Lessons to Be Learned
Web Address:
http://www.researchandmarkets.com/reports/363611
Office Code:
OC8HJMRPRTPXY

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €748.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 21/11/2009 23:27:09

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)